Cidara Therapeutics, Inc. (CDTX)
$221.38+0.00%Close
BUYBULL · day 32
Key stats
- Market cap
- $5.6B
- Beta
- 1.53
- P/E (TTM)
- -46.61
- 1W
- +0.22%
- 1M
- +0.60%
- vs SPY 1W
- -0.94%
- vs SPY 1M
- -2.40%
Industry peers
FMP comparable companies · ranked by market cap
- SRRKSELLScholar Rock Holding Corporation$5.1BCRISISQ 22$42.20-0.02%
- ADPTBUYAdaptive Biotechnologies Corporation$4.2BCRISISQ 6$26.09+1.53%
- CPRXBUYCatalyst Pharmaceuticals, Inc.$3.9BBULLQ 20$31.49+0.00%
- LEGNSELLLegend Biotech Corporation$3.5BRECOVERYQ 2$18.71-0.48%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.06+0.14%
- ZLABSELLZai Lab Limited$2.8BRECOVERYQ 9$24.81+0.73%
- BEAMBUYBeam Therapeutics Inc.$2.5BRECOVERYQ 14$24.60+4.47%
- IRONSELLDisc Medicine, Inc.$2.3BCRISISQ 1$60.77+2.12%
- MLYSSELLMineralys Therapeutics, Inc.$2.0BCRISISQ 19$22.38+4.42%
- AGIOSELLAgios Pharmaceuticals, Inc.$1.9BRECOVERYQ 4$31.92-0.34%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on CDTX?
- LOPJLB’s latest quantitative signal on Cidara Therapeutics, Inc. (CDTX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is CDTX in?
- Cidara Therapeutics, Inc. (CDTX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Cidara Therapeutics, Inc. (CDTX) do?
- Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert…